Application of commercial research-grade biomarker assays in drug development: is it time to create ‘pharmaceutical-grade’ kits?

“In pharmaceutical/biotechnology companies, the demand for increased innovation and efficiency has never been greater, but, at the same time, there is a profound need to reduce the overall cost associated with the development of new therapeutics.” Today, the application of biomarkers is routinely included as an integral component in pharmaceutical/biotechnology R&D strategies to improve the success rate and cost–effectiveness of rational drug development [1–3]. This notion is illustrated nicely by a PubMed search in which biomarkers and drug development were used in combination as search terms to gauge the growth in publication rate between 1990 and 2010. This topical search...

To view this content, please register now for access

It's completely free